IRF2 and hepatocellular carcinoma: To determine the effect of lenvatinib treatment on IRF2 and β-catenin expression in HCC cells, HepG2 and Huh7 cells were treated with 0, 2.5, or 7.5 μM of lenvatinib for 48 h or 72 h.